Modern Care Journal

Published by: Kowsar

Follow-Up of Chronic Hepatitis B Carriers: A Cross-Sectional Descriptive-Analytical Study

Tahereh Darvishpoor Kakhki 1 , Bita Bigari 2 , Ghodsiyeh Azarkar 2 and Masood Ziaee 2 , *
Authors Information
1 Ophthalmologist Resident, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Infectious Disease Research Center, Birjand University of Medical Sciences, Birjand, Iran
Article information
  • Modern Care Journal: January 2017, 14 (1); e64726
  • Published Online: December 28, 2016
  • Article Type: Research Article
  • Received: February 16, 2016
  • Accepted: March 26, 2016
  • DOI: 10.5812/modernc.64726

To Cite: Darvishpoor Kakhki T, Bigari B, Azarkar G, Ziaee M. Follow-Up of Chronic Hepatitis B Carriers: A Cross-Sectional Descriptive-Analytical Study, Mod Care J. 2017 ; 14(1):e64726. doi: 10.5812/modernc.64726.

Copyright © 2017, Modern Care Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Malekzadeh R, Malekzadeh Z. Hepatitis B virus in Iran epidemiology, liver cell damage and clinical procedure [In Persian]. Govaresh. 2010;14(4):226-34.
  • 2. Ziaee M, Javanmard D, Sharifzadeh G, Hasan Namaei M, Azarkar G. Genotyping and Mutation Pattern in the Overlapping MHR Region of HBV Isolates in Southern Khorasan, Eastern Iran. Hepat Mon. 2016;16(10). e37806. doi: 10.5812/hepatmon.37806. [PubMed: 27882062].
  • 3. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010;14 Suppl 3:e113-6. doi: 10.1016/j.ijid.2009.11.032. [PubMed: 20362479].
  • 4. World Health Organization . Introduction of hepatitis B vaccine into childhood immunization services: Management guidelines, including information for health workers and parents. 2001.
  • 5. Salehi-Vaziri M, Sadeghi F, Almasi Hashiani A, Gholami Fesharaki M, Alavian SM. Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis. Hepat Mon. 2016;16(4). e35577. doi: 10.5812/hepatmon.35577. [PubMed: 27257428].
  • 6. Ziaee M, Ebrahimzadeh A, Azarkar Z, Namaei MH, Saburi A, Fereidouni M, et al. Seroprevalence and Risk Factors for Hepatitis B in an Adult Population: The First Report from Birjand, South Khorasan, Iran. Hepat Mon. 2016;16(9). e36452. doi: 10.5812/hepatmon.36452. [PubMed: 27822260].
  • 7. Kheiri L, Makvandi S. The prevalence of hepatitis B surface antigen (HBsAg) and its influencing factors in pregnant women referring to healthcare centers of dehloran, Iran in 2011-2012. J Midwifery Reprod Health. 2015;3(3):424-9. doi: 10.22038/jmrh.2015.4313.
  • 8. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403-6. [PubMed: 18193122].
  • 9. T.R. H . Harrison's principles of internal medicine. 18th ed. 2. MCGraw-Hill companies; 2012. p. 2567-77.
  • 10. Hassanjani Roshan MR, Ramezani A. Long-term follow up of chronic Hbv carriers in Babol 1991-2000. Iran J Infect Dis Tropical Med. 2002;7(16):15-20.
  • 11. Bortolotti F, Jara P, Crivellaro C, Hierro L, Cadrobbi P, Frauca E, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol. 1998;29(2):184-90. doi: 10.1016/S0168-8278(98)80002-0. [PubMed: 9722198].
  • 12. Kato Y, Nakao K, Hamasaki K, Kato H, Nakata K, Kusumoto Y, et al. Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan. J Gastroenterol. 2000;35(3):201-5. doi: 10.1007/s005350050331. [PubMed: 10755689].
  • 13. Zacharakis GH, Koskinas J, Kotsiou S, Papoutselis M, Tzara F, Vafeiadis N, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol. 2005;77(2):173-9. doi: 10.1002/jmv.20434. [PubMed: 16121378].
  • 14. Jagannathan L, Chaturvedi M, Mudaliar S, Kamaladoss T, Rice M, Murphy EL. Risk factors for chronic hepatitis B virus infection among blood donors in Bangalore, India. Transfus Med. 2010;20(6):414-20. doi: 10.1111/j.1365-3148.2010.01032.x. [PubMed: 20726953].
  • 15. Morgan M, Keeffe EB. Diagnosis and treatment of chronic hepatitis B: 2009 update. Minerva Gastroenterol Dietol. 2009;55(1):5-22. [PubMed: 19212304].
  • 16. Chen XF, Chen XP, Ma XJ, Chen WL, Luo XD, Liao JY. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment]. Zhonghua Gan Zang Bing Za Zhi. 2013;21(7):502-5. doi: 10.3760/cma.j.issn.1007-3418.2013.07.007. [PubMed: 24074707].
  • 17. Yan HD, Jiang FR, Zhu CL, Gao GS, Weng PJ, Hu AR, et al. [Liver histopathological features influencing HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B responding to Peg-IFN treatment]. Zhonghua Gan Zang Bing Za Zhi. 2013;21(5):340-4. doi: 10.3760/cma.j.issn.1007-3418.2013.05.007. [PubMed: 24025133].
  • 18. Maklad S, Esmat G, Doss W, Abou-Zeid A, El-Din SS. Response and seroconversion rates among HBeAg-positive chronic HBV Egyptian patients treated with peginterferon alpha 2a (Pegasys), a single-centre experience. Arab J Gastroenterol. 2013;14(2):73-7. doi: 10.1016/j.ajg.2013.04.001. [PubMed: 23820505].
  • 19. Yalcin K, Degertekin H, Yildiz F, Celik Y. Markers of disease activity in chronic hepatitis B virus infection. Clin Invest Med. 2003;26(1):27-34. [PubMed: 12659467].
  • 20. Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, et al. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat. 2010;17(2):115-22. doi: 10.1111/j.1365-2893.2009.01168.x. [PubMed: 19874478].
  • 21. Ziaee M, Azarkar G. Prevalence of hepatitis d virus infection among patients with chronic hepatitis B attending birjand hepatitis clinic (East of iran) in 2012. Hepat Mon. 2013;13(8). e11168. doi: 10.5812/hepatmon.11168. [PubMed: 24171009].
  • 22. Ghadir MR, Belbasi M, Heidari A, Sarkeshikian SS, Kabiri A, Ghanooni AH, et al. Prevalence of hepatitis d virus infection among hepatitis B virus infected patients in qom province, center of iran. Hepat Mon. 2012;12(3):205-8. doi: 10.5812/hepatmon.847. [PubMed: 22550529].
  • 23. Amini N, Alavian SM, Kabir A, Saiedi Hosseini SY, Aalaei Andabili SH. Clinical Features and Seroepidemiology of Anti-HDV Antibody in patients With Chronic Hepatitis B Virus Infection in Iran: A Meta-Analysis. Hepat Mon. 2011;11(12):960-7. doi: 10.5812/kowsar.1735143X.805. [PubMed: 22368679].
  • 24. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int. 2009;3(3):425-33. doi: 10.1007/s12072-009-9140-3. [PubMed: 19669245].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments